{
  "ticker": "ANO",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02967824",
  "id": "02967824",
  "pages": 1,
  "price_sensitive": false,
  "date": "20250709",
  "time": "1520",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250709/pdf/06ln0r5wh7340l.pdf",
  "summary": "- **Key Impact on Valuation/Liquidity**:  \n  - 200% tariff threat on Australian pharmaceutical companies (exemptions for zinc oxide).  \n  - Potential relocation of operations to the US to avoid tariffs (feasible due to automation/control from Australia).  \n  - Competitive advantage: ANO\u2019s products face 0% tariff vs. 25% for Japan/South Korea competitors.  \n- **Capital Markets Consideration**:  \n  - No immediate negative impact on US business expected.  \n  - Australian government negotiations may alter outcome.  \n\n*Omitted non-material details (e.g., relocation history, director authorization).*",
  "usage": {
    "prompt_tokens": 493,
    "completion_tokens": 132,
    "total_tokens": 625,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-09T05:54:43.226638"
}